NCT01646762View on ClinicalTrials.gov

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed or Refractory Multiple Myeloma

PHASE2TerminatedINTERVENTIONAL

Enrollment

13

Participants

Timeline

Start Date

November 5, 2012

Primary Completion Date

January 15, 2015

Study Completion Date

October 27, 2015

Conditions

Refractory Plasma Cell Myeloma

Interventions

DRUG

Paclitaxel Albumin-Stabilized Nanoparticle Formulation

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

85259

Mayo Clinic in Arizona, Scottsdale

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER